Our survival analysis for each of the factors we suspect may lead to cancer progression and negative clinical outcomes demonstrated that patients with lower eIF4E expression had a statistically significant lower rate of cancer recurrence, when compared with those patients with higher eIF4E expression (p = 0.006, log-rank test). This evidence concerns the gene EIF4E and cancer.